Get the Stockscreener App
6.23
3.41%
-0.22
After Hours:
6.10
-0.13
-2.09%
Personalis Inc stock is traded at $6.23, with a volume of 1.37M.
It is down -3.41% in the last 24 hours and up +25.86% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$6.45
Open:
$6.39
24h Volume:
1.37M
Relative Volume:
1.79
Market Cap:
$488.44M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-2.7689
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
+12.66%
1M Performance:
+25.86%
6M Performance:
+62.24%
1Y Performance:
+384.82%
1-Day Range:
$6.215
$6.72
1-Week Range:
$5.502
$6.72
52-Week Range:
$1.135
$7.20
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
6.23 | 488.44M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
390.26 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
195.75 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
520.59 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.09 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
154.10 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Personalis: Ultra-Sensitive Tech, Ultra-Sensitive Risks (NASDAQ:PSNL) - Seeking Alpha
Two Sigma Advisers LP Grows Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Shares Purchased by Two Sigma Investments LP - Defense World
Ameriprise Financial Inc. Has $199,000 Holdings in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Bank of America Corp DE Sells 30,474 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-Therapy - MSN
Personalis reveals ctDNA test predicts cervical cancer relapse By Investing.com - Investing.com South Africa
Personalis reveals ctDNA test predicts cervical cancer relapse - Investing.com Australia
Personalis (PSNL) Blood Test Shows Promise in Detecting Cervical Cancer Early | PSNL Stock News - GuruFocus
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO - Yahoo Finance
Personalis Says Studies Show NeXT Personal Test Could Identify Relapse Risk in Breast Cancer Patients - marketscreener.com
Personalis (PSNL) Showcases Promising Results for NeXT Personal in Breast Cancer Care | PSNL Stock News - GuruFocus
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse - Yahoo Finance
Northern Trust Corp Lowers Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Millennium Management LLC Has $7.61 Million Stock Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
BNP Paribas Financial Markets Acquires 71,721 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis and Academic Partners to Present Latest Data on Ultra - GuruFocus
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection - Yahoo Finance
New Clinical Data Reveals Groundbreaking Early Cancer Detection ResultsPersonalis ASCO Preview - Stock Titan
Personalis Holds Virtual Annual Stockholders Meeting - TipRanks
PSNL to Discuss Future Plans in Upcoming Virtual Meeting | PSNL Stock News - GuruFocus
Brokerages Set Personalis, Inc. (NASDAQ:PSNL) PT at $8.00 - Defense World
Personalis Inc (PSNL): A Sitting Duck With -162.63% Upside Potential - Stocksregister
Guggenheim Begins Coverage on Personalis (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Stake Raised by Jane Street Group LLC - Defense World
Jane Street Group LLC Has $2.32 Million Stock Holdings in Personalis, Inc. (NASDAQ:PSNL) - The AM Reporter
Personalis, Inc. (NASDAQ:PSNL) Shares Acquired by Stifel Financial Corp - Defense World
Guggenheim Initiates Buy Rating for Personalis (PSNL) with $6 Ta - GuruFocus
Guggenheim starts Personalis with a Buy, cites ‘best-in-class infrastructure’ - TipRanks
Guggenheim Initiates Buy Rating for Personalis (PSNL) with $6 Target | PSNL Stock News - GuruFocus
Guggenheim Initiates Personalis at Buy With $6 Price Target - marketscreener.com
Guggenheim Starts Coverage on Personalis (PSNL) with Buy Rating - GuruFocus
Guggenheim Starts Coverage on Personalis (PSNL) with Buy Rating | PSNL Stock News - GuruFocus
Dimensional Fund Advisors LP Purchases 242,141 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Raymond James Financial Inc. Takes Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Leading Genomics Company Personalis Takes Center Stage at Major Craig-Hallum Investor Conference - Stock Titan
Personalis stock price target raised to $9 at H.C. Wainwright By Investing.com - Investing.com Nigeria
What is HC Wainwright’s Estimate for Personalis Q2 Earnings? - Defense World
Personalis reiterates 2025 revenue guidance of $80M-$90M with focus on MRD testing growth - MSN
HC Wainwright Raises Personalis (NASDAQ:PSNL) Price Target to $9.00 - Defense World
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - MSN
Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth - Yahoo Finance
Barclays PLC Acquires 43,900 Shares of Personalis, Inc. (NASDAQ:PSNL) - The AM Reporter
JPMorgan Chase & Co. Has $34,000 Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Barclays PLC Increases Stock Holdings in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis stock price target raised to $9 at H.C. Wainwright - Investing.com Australia
Personalis Inc.: Strong Financial Performance and Promising Future Prospects Drive Buy Rating - TipRanks
Will Personalis' Testing Growth And MRD Strategy Pay Off In 2025? - Nasdaq
Analyst Expectations For Personalis's Future - Benzinga
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):